Ongoing
Research Projects |
- A Study to Compare Long-Term Safety and Tolerability of Stavudine (D4T) Extended
Release (ER) Versus Conventional (Immediate Release, IR)
Formulations. Each in Combination with Lamivudine (3TC)
and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies
A1455-096 and A1455-099.
- An Open-Label Study of the Antiviral Efficacy and Safety of a Novel HIV-1 Protease
Inhibitor, BMS-232632, Versus Lopinavir/Ritonavir (LPV/RTV)
in Combination with Two Nucleosides in Subjects Who Have
Experienced Virologic Failure with Prior Protease Inhibitor-Containing
HAART Regimen (s).
- A Phase III, Randomized, Double-Blind, Multicenter Study to Assess the Safety
and Efficacy of DPC-083 versus Nelfinavir. Each in Combination
with Combivir (Zidivudine and Lamivudine), in Antiretroviral-Naïve
HIV-1 Infected Subjects (2000-present).
- A Phase III, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy,
Safety, and Tolerability of DPC-083 Versus Kaletra in Combination
with Open-Label NRTIs in NNRTI-Naïve HIV-1 infected Subjects
Who Have Failed Their First and Only Antiretroviral Treatment
Regimen, Which Must Have Contained A Single, Non-Boosted
PI And Two NRTIs (2000-present).
- A Phase II/III, 48wk, Randomized, Double-Blind, Controlled, Multicenter Study
To Evaluate The Efficacy And Safety Of Lamivudine 300mg,
Once Daily Vs Lamivudine 150mg BID In Combination With Zidovudine
300mg BID And Efavirenz 600mg Once Daily In Antiretroviral
Naïve Adults With HIV-1 Infection (2000-present).
- A Phase II/III, 56 Wk, Randomized, Double-Blind, The Safety And Antiviral Efficacy
Of Stavudine Extended Release Formulation As Compared To
Stavudine Immediate Release Formulation, Each As Part Of
Potent Antiretroviral Combination Therapy (2000-present).
- A Phase II/III, 56 Wk, Randomized, Double-Blind, The Safety And Antiviral Efficacy
Of Stavudine Extended Release Formulation As Compared To
Stavudine Immediate Release Formulation, Each As Part Of
Potent Antiretroviral Combination Therapy (2000-present).
|
